Key result
Patients developing cardiometabolic multimorbidity via the trajectory from cardiovascular to metabolic disease had a significantly greater mortality risk compared to those with a single metabolic disease (HR 3.32).
Why the study?
Does the trajectory of cardiometabolic multimorbidity progression affect mortality risk in adults?
Cohort (n=34,244)
Yes
Does the trajectory of cardiometabolic multimorbidity progression affect mortality risk in adults?
Answers are grounded in this paper and cite their sources.
The sequence of cardiometabolic disease onset significantly impacts mortality, with the cardiovascular-to-metabolic trajectory carrying the highest risk.
Background: Cardiometabolic multimorbidity (CMM) prevalence has risen, but longitudinal evidence on trajectories and mortality links remains limited. Objective: This study aimed to examine CMM trends and the impact of its statuses/trajectories on mortality in Guangdong, China. Design: This is a cohort study. Setting: Data were collected from the Guangdong Provincial adult chronic diseases and risk factors cohort (GDACRC). The follow-up data were collected from the hospitalization record system and the vital register system in Guangdong Province. Participants: Baseline surveys were separately conducted in 2007, 2010, 2013, 2015, and 2018, which recruited 34,244 participants aged 18 years or older. Measurements: Calculated age-sex standardized CMM prevalence. Cox proportional hazards models were used to assess the associations between CMM statuses/trajectories and mortality risk. Compared with participants without any cardiometabolic diseases (CMD), the mortality risk of those with single CMD and CMM, respectively, increased by 30 and 85%, with a greater risk of patients aged < 65 years. The most common trajectory was from metabolic disease (M) to cardiovascular diseases (C), that 9.31% healthy participants at baseline developed CMM on this trajectory, which accounted for 53.5% of all CMM patients. Compared to patients with single M, patients with the trajectory from C to M had greater mortality risk (HR = 3.32, 95% CI: 2.13-5.16). Limitation: Single-province sample; self-report bias. Conclusion: CMM represents a major public health challenge in Guangdong Province, China. Our findings provide new insights on the CMM progression, which may be helpful for prevention and clinical management of CMM.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) conducted a cohort in Cardiometabolic multimorbidity (CMM) (n=34,244). Cardiometabolic multimorbidity trajectory (cardiovascular to metabolic disease) vs. Single metabolic disease was evaluated on All-cause mortality (HR 3.32, 95% CI 2.13-5.16). Patients developing cardiometabolic multimorbidity via the trajectory from cardiovascular to metabolic disease had a significantly greater mortality risk compared to those with a single metabolic disease (HR 3.32).
Synapse has enriched 10 related papers. Consider them for comparative context: